In The Field - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

In The Field

Pharmaceutical Technology


The new Abraxis BioScience, as a standalone publicly traded company, will have its headquarters in Los Angeles, California, and will employ more than 500 people. The executive committee of Abraxis BioScience will remain in their current positions. The new board of directors for this business will be determined before, or at the close of, the transaction. -Patricia Van Arnum

Company Notes

Cambridge, MA (June 7)—Genzyme Corp. is investing nearly $140 million in a new 140,000-ft2 biomanufacturing plant in Lyon, France, to replace its smaller plant in nearby Marcy l'Etoile. The new plant, which will be used to manufacture Genzyme's transplantation treatment, "Thymoglobulin," will have more than twice the manufacturing capacity of the Marcy facility. Genzyme also is developing a plant in Belgium to produce monoclonal antibodies and proteins, and intends to expand its Allston Landing protein plant in Boston.


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
70%
Breakthrough designations
4%
Protecting the supply chain
17%
Expedited reviews of drug submissions
2%
More stakeholder involvement
7%
View Results
Eric Langerr Outsourcing Outlook Eric LangerRelationship-building at Top of Mind for Clients
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerRisk Reduction Top Driver for Biopharmaceutical Raw Material Development
Jill Wechsler Regulatory Watch Jill Wechsler Changes and Challenges for Generic Drugs
Faiz Kermaini Industry Insider Faiz KermainiNo Signs of a Slowdown in Mergers
Ebola Outbreak Raises Ethical Issues
Better Comms Means a Fitter Future for Pharma, Part 2: Realizing the Benefits of Unified Communications
Better Comms Means a Fitter Future for Pharma, Part 1: Challenges and Changes
Sandoz Wins Biosimilar Filing Race
NIH Translational Research Partnership Yields Promising Therapy
Source: Pharmaceutical Technology,
Click here